James A. Robinson Jr.
CIK: 0001734295
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jan 10, 2035ELDN
Eledon Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30.9K shares- - Aug 26, 2026URGN
UroGen Pharma Ltd.
Exercise(M)Direct2K shares- - Jun 22, 2026URGN
UroGen Pharma Ltd.
Award(A)DirectRestricted Stock Unit
8K shares- - Jun 22, 2026URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
10K shares- - May 26, 2026URGN
UroGen Pharma Ltd.
Exercise(M)Direct2K shares- - Jan 10, 2026ELDN
Eledon Pharmaceuticals, Inc.
Exercise(M)Direct3.4K shares- - Nov 26, 2025URGN
UroGen Pharma Ltd.
Exercise(M)Direct2K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
10K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectRestricted Stock Unit
8K shares- - Feb 26, 2025URGN
UroGen Pharma Ltd.
Exercise(M)Direct2K shares- - Jan 10, 2025ELDN
Eledon Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
3.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 10, 2035 |  ELDN Eledon Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,870 | - | - | Direct |
| Aug 26, 2026 |  URGN UroGen Pharma Ltd. | Exercise(M) | 2,000 | - | $0 | Direct |
| Jun 22, 2026 | URGN UroGen Pharma Ltd. | Award(A) Restricted Stock Unit | 8,000 | - | - | Direct |
| Jun 22, 2026 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 10,000 | - | - | Direct |
| May 26, 2026 | URGN UroGen Pharma Ltd. | Exercise(M) | 2,000 | - | $0 | Direct |
| Jan 10, 2026 | ELDN Eledon Pharmaceuticals, Inc. | Exercise(M) | 3,430 | - | $0 | Direct |
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | Exercise(M) | 2,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 10,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Restricted Stock Unit | 8,000 | - | - | Direct |
| Feb 26, 2025 | URGN UroGen Pharma Ltd. | Exercise(M) | 2,000 | - | $0 | Direct |
| Jan 10, 2025 | ELDN Eledon Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 3,430 | - | - | Direct |
1-11 of 11 transactions
About Robinson James A. Jr.
Robinson James A. Jr. (SEC CIK 0001734295) files insider reports with the SEC as Director of UroGen Pharma Ltd. (URGN) and Director of Eledon Pharmaceuticals, Inc. (ELDN).
Signal8 holds 8 ownership filings by Robinson James A. Jr., all Form 4s, filed between Jan 13, 2025 and Aug 28, 2026. Those filings report 11 transactions, from Jan 10, 2025 to Aug 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Robinson James A. Jr.'s filings is in PRINCETON, NJ.
Recent filings by Robinson James A. Jr.
- Jan 10, 2035: Grant or award of ELDN derivative securities (Form 4, code A).
- Aug 26, 2026: Option exercise of URGN shares (Form 4, code M).
- Jun 22, 2026: Grants or awards of URGN derivative securities (2 lines, Form 4, code A).
- May 26, 2026: Option exercise of URGN shares (Form 4, code M).
- Jan 10, 2026: Option exercise of ELDN shares (Form 4, code M).
Other insiders filing for UroGen Pharma Ltd. (URGN)
- Degnan Chris, Chief Financial Officer
- Schoenberg Mark, Chief Medical Officer
- Smith Jason Drew, General Counsel
- Wildman Daniel George, Director
- Holden Stuart, Director
- BUTITTA CYNTHIA M, Director